Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

Core Viewpoint - Anavex Life Sciences Corp. is advancing its clinical pipeline, particularly focusing on its lead candidate, oral blarcamesine, for early Alzheimer's disease, with a commitment to improving the lives of patients with neurological disorders [2][3]. Financial Highlights - Cash and cash equivalents increased to $131.7 million as of December 31, 2025, compared to $102.6 million at September 30, 2025, indicating a cash runway of more than 3 years at the current utilization rate [11]. - Research and development expenses for the quarter were $4.7 million, down from $10.4 million in the comparable quarter of fiscal 2025 [11]. - General and administrative expenses decreased to $2.1 million from $3.1 million in the same period last year [11]. - The net loss for the quarter was $5.7 million, or $0.06 per share, compared to a net loss of $12.1 million, or $0.14 per share for the comparable fourth quarter of fiscal 2025 [11]. Recent Corporate Developments - Anavex is making progress on its clinical development program for Parkinson's disease and has updates on regulatory pathways for blarcamesine in both early Alzheimer's disease and Rett syndrome [6]. - The company announced its participation in ACCESS-AD, a European initiative aimed at accelerating innovative diagnostic and therapeutic approaches for Alzheimer's disease [6]. - Wolfgang Liedtke, MD PhD, was appointed as Senior Vice President, Global Head of Neurology, bringing over 25 years of experience in CNS diseases [6]. Expected Development Milestones - Upcoming presentations include an oral presentation at the 16th Intrinsic Capacity, Frailty and Sarcopenia Research Conference, focusing on the treatment of older adults with pre-frailty using oral blarcamesine [6]. - Anavex plans to submit existing data from the Phase IIb/III ANAVEX2-73-AD-004 program to the FDA to support a New Drug Application for Alzheimer's disease [11].